Prosecution Insights
Last updated: April 19, 2026
Application No. 17/605,794

Cytidine Derivatives and Methods of Forming Cytidine Derivatives

Non-Final OA §112
Filed
Oct 22, 2021
Examiner
BAKSHI, PANCHAM
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Aenorasis Commercial Company Of Pharmaceutical And Medical Products And Machines Societe Anonyme
OA Round
3 (Non-Final)
77%
Grant Probability
Favorable
3-4
OA Rounds
2y 5m
To Grant
99%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allow Rate
873 granted / 1132 resolved
+17.1% vs TC avg
Strong +30% interview lift
Without
With
+30.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
77 currently pending
Career history
1209
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
32.0%
-8.0% vs TC avg
§102
23.0%
-17.0% vs TC avg
§112
27.0%
-13.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1132 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 09/15/2025 has been entered. Status of the Application Claims 1, 4-11, 13, 15-32, 36-40 are pending, of which claims 8, 21-32 and 36-40 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 1, 4-7, 9-11, 13 and 15-20 are under current examination. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 18 rejected under 35 U.S.C. 112(b), as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 18 is indefinite as the claim recites narrow and broad limitations within the same claim. Applicant in response corrected the issue at some instances but left the issue in several other places. For instance, Ar is A1—A5 and are each independently H, NO2, OH--- optionally, ---A1 is NO2 and A2---are H---A3, A4—O-methyl ----”. Thus, scope of claim is unclear. For compact prosecution, the claims have been interpreted with broader limitation. Appropriate correction required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), fourth paragraph: Subject to the [fifth paragraph of 35 U.S.C. 112 (pre-AIA )], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 19 is rejected under 35 U.S.C. 112(d), as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 19 is in an improper dependent form because Claim 19 recites “R1 comprises a substituent reactive with the---(III)”, which is a broader limitation than claim 1. Claim 1 specifies R1 group and not to group with a functional definition of any structure that may react with (III). Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Response to arguments Applicant’s remarks and amendment, as filed on 09/15/2025, have been fully considered but not found persuasive. Applicant argued over rejection under 112b that the amended claims obviate the rejection. Applicant argued over rejection under 112d that the amended claims obviate the rejection. This is not found persuasive and the instant claims stand rejected under 112b. This is because applicant made a couple of amendments correcting the issue of broad and narrow limitations within the same claim. However, the corrections were not made in the entire claim. There are several instances left in the instant claim that recites narrow and broad limitations within the same claim. Applicant is suggested to make corrections. Applicant argued over rejection under 112d that the amended claims obviate the rejection. This is not found persuasive and the instant claims stand rejected under 112d. This is because the claim still recites same issue with respect to 112d. Applicant is suggested to make corrections. Allowable Subject matter Claims 1, 4-7, 9-11, 13, 15-17 and 20 present allowable subject matter over the cited prior art on record. Conclusion Claims 1, 4-7, 9-11, 13, 15-17 and 20 are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PANCHAM BAKSHI whose telephone number is (571)270-3463. The examiner can normally be reached M-Thu 7-4.30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Milligan Adam can be reached at 571-2707674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PANCHAM BAKSHI/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Oct 22, 2021
Application Filed
Oct 22, 2021
Response after Non-Final Action
May 13, 2022
Response after Non-Final Action
Jan 15, 2025
Non-Final Rejection — §112
Apr 18, 2025
Response Filed
Jun 11, 2025
Final Rejection — §112
Sep 15, 2025
Request for Continued Examination
Sep 17, 2025
Response after Non-Final Action
Oct 22, 2025
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595353
PLASTICIZER COMPOSITION AND RESIN COMPOSITION COMPRISING THE SAME
2y 5m to grant Granted Apr 07, 2026
Patent 12594293
USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS
2y 5m to grant Granted Apr 07, 2026
Patent 12590162
CANCER TREATMENT
2y 5m to grant Granted Mar 31, 2026
Patent 12565514
NUCLEIC ACID CONTAINING PERFLUOROALKYL GROUP, AND METHOD FOR ITS PRODUCTION
2y 5m to grant Granted Mar 03, 2026
Patent 12565466
SYNTHESIS AND USE OF PRECURSORS FOR VAPOR DEPOSITION OF TUNGSTEN CONTAINING THIN FILMS
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
77%
Grant Probability
99%
With Interview (+30.4%)
2y 5m
Median Time to Grant
High
PTA Risk
Based on 1132 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month